Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

skin check

- PMLiVE

Gilead expands IT partnership with Cognizant in deal worth approximately $800m

It is hoped that the collaboration will enable Gilead to bring its medicines to market faster

- PMLiVE

Moderna and Merck’s skin cancer vaccine enters late-stage development

More than 1,000 patients with resected high-risk melanoma will be enrolled in the trial

- PMLiVE

AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

The long-term inflammatory skin condition affects an estimated 1% of the global population

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by CHMP for expanded melanoma use

The global incidence of skin cancer has been rising steadily over the past few decades

Engaging KOLs & Gaining Insights in Pharma’s New Normal

Kaitlin Anstett, Senior Medical Advisor at Theratechnologies, shares her unique insights into the way Medical Affairs teams are changing the way they are engaging and interacting with their most important...

Impetus Digital

Mobilizing Agitation Detection in Children with ADHD

Marius Rus, founder of StressLess–the startup behind Tully–discusses wearable technologies for children with ADHD, autism, and other mental health conditions. He also shares his tips and lessons learned from founding...

Impetus Digital

- PMLiVE

Incyte shares positive results for Opzelura cream in children with atopic dermatitis

Two to three million children aged two to 11 years in the US are affected by atopic dermatitis

- PMLiVE

Almirall’s Ilumetri shown to improve well-being of patients with plaque psoriasis

Almost 77% of psoriasis patients report that the condition negatively affects their well-being

How to Increase Engagement During Virtual Events

Tip #4 - How do you plan the agenda for your virtual event? We suggest to invite participant input to build and personalize the engagement. Check out our full top...

Impetus Digital

- PMLiVE

Galderma’s nemolizumab shows promise in phase 3 prurigo nodularis trial

The condition affects more than 70 out of every 100,000 adults aged 18 to 64 years in the US

- PMLiVE

Janssen announces positive phase 2b results for JNJ-2113 in plaque psoriasis

The immune-mediated disease is estimated to affect more than 125 million people worldwide

- PMLiVE

Boehringer’s spesolimab shows promise in generalised pustular psoriasis prevention

The therapy prevented flares in patients with the chronic skin disease for over 48 weeks

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links